Effects of Vasocon-A in the allergen challenge model of acute allergic conjunctivitis.
The ophthalmic combination product of 0.05% naphazoline hydrochloride and 0.5% antazoline phosphate (Vasocon-A) was evaluated as an antiallergic agent in 100 subjects with a known allergic history to cat dander, ragweed, or bluegrass pollen. Three independent study sites were used. The allergen challenge model of acute allergic conjunctivitis was selected to assess the agent as it provided a standardized and precise way to measure drug effectiveness for this indication. In a double-masked randomized fashion, the subjects were assigned to one of three groups that received one drop of Vasocon-A in one eye and one drop of either 0.05% naphazoline (group 1), 0.5% antazoline (group 2), or placebo (group 3) in the contralateral eye. After 10 minutes, the dose of allergen shown to elicit a 2+ redness and itching reaction was instilled bilaterally. Signs and symptoms of allergic conjunctivitis were evaluated after 3, 5, and 10 minutes. Subjects were then rechallenged 2 hours after drug administration to assess the duration of action of the agents. Vasocon-A was found to significantly inhibit all five major signs and symptoms of allergic conjunctivitis: itching, redness, chemosis, lid swelling, and tearing, for more than 85% of the comparisons when compared over time with placebo, naphazoline alone, or antazoline alone. The results of this study indicate that the combination of naphazoline and antazoline was more effective in inhibiting redness than naphazoline and more effective in inhibiting itching than antazoline. These findings support the use of such a combination for the treatment of allergic conjunctivitis.
Abelson
M B
MB
Department of Ophthalmology, Harvard Medical School, Boston, MA.
Paradis
A
A
George
M A
MA
Smith
L M
LM
Maguire
L
L
Burns
R
R
D000485:Allergens / Q000008:administration & dosage; D000865:Antazoline / Q000627:therapeutic use*; D003228:Conjunctiva / Q000187:drug effects; D003233:Conjunctivitis, Allergic / Q000188:drug therapy*; D004338:Drug Combinations / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D006940:Hyperemia / Q000188:drug therapy; D007093:Imidazoles / Q000627:therapeutic use*; D009278:Naphazoline / Q000627:therapeutic use*
D000485:Allergens; D004338:Drug Combinations; D007093:Imidazoles; C051139:antazoline sulfate, naphazoline mononitrate drug combination; D000865:Antazoline; D009278:Naphazoline